Baerbel Rotthaeuser
Frankfurt Am Main, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design.
Journal: Diabetes, obesity & metabolism
Published: December 22, 2025
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
Journal: Journal of diabetes science and technology
Published: February 29, 2024
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Journal: Diabetes, obesity & metabolism
Published: August 11, 2023
In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
Journal: Journal of pharmaceutical sciences
Published: August 08, 2022
Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy.
Journal: Indian journal of endocrinology and metabolism
Published: May 31, 2022
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 28, 2022
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: January 14, 2022
Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
Journal: Journal of diabetes science and technology
Published: January 24, 2018
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
Journal: Diabetes, obesity & metabolism
Published: August 31, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026